
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1651866/publications.pdf Version: 2024-02-01



LUICI RADTALENA

#	Article	IF	CITATIONS
1	The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy. European Thyroid Journal, 2016, 5, 9-26.	2.4	738
2	Relation between Therapy for Hyperthyroidism and the Course of Graves' Ophthalmopathy. New England Journal of Medicine, 1998, 338, 73-78.	27.0	644
3	Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO. European Journal of Endocrinology, 2008, 158, 273-285.	3.7	611
4	2018 European Thyroid Association Guideline for the Management of Graves' Hyperthyroidism. European Thyroid Journal, 2018, 7, 167-186.	2.4	544
5	Management of Graves' Ophthalmopathy: Reality and Perspectives*. Endocrine Reviews, 2000, 21, 168-199.	20.1	527
6	Selenium and the Course of Mild Graves' Orbitopathy. New England Journal of Medicine, 2011, 364, 1920-1931.	27.0	503
7	Epidemiology and Prevention of Graves' Ophthalmopathy. Thyroid, 2002, 12, 855-860.	4.5	390
8	The Effects of Amiodarone on the Thyroid*. Endocrine Reviews, 2001, 22, 240-254.	20.1	389
9	The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy. European Journal of Endocrinology, 2021, 185, G43-G67.	3.7	362
10	Consensus Statement of the European Group on Graves' Orbitopathy (EUGOGO) on Management of Graves' Orbitopathy. Thyroid, 2008, 18, 333-346.	4.5	342
11	Use of Corticosteroids to Prevent Progression of Graves' Ophthalmopathy after Radioiodine Therapy for Hyperthyroidism. New England Journal of Medicine, 1989, 321, 1349-1352.	27.0	296
12	Graves' Ophthalmopathy. New England Journal of Medicine, 2009, 360, 994-1001.	27.0	287
13	Orbital Cobalt Irradiation Combined with Systemic Corticosteroids for Graves' Ophthalmopathy: Comparison with Systemic Corticosteroids Alone*. Journal of Clinical Endocrinology and Metabolism, 1983, 56, 1139-1144.	3.6	282
14	Efficacy and Safety of Three Different Cumulative Doses of Intravenous Methylprednisolone for Moderate to Severe and Active Graves' Orbitopathy. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 4454-4463.	3.6	282
15	Prevalence and Natural History of Graves' Orbitopathy in a Large Series of Patients With Newly Diagnosed Graves' Hyperthyroidism Seen at a Single Center. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 1443-1449.	3.6	253
16	Cigarette Smoking and Treatment Outcomes in Graves Ophthalmopathy. Annals of Internal Medicine, 1998, 129, 632.	3.9	243
17	Comparison of the Effectiveness and Tolerability of Intravenous or Oral Glucocorticoids Associated with Orbital Radiotherapy in the Management of Severe Graves' Ophthalmopathy: Results of a Prospective, Single-Blind, Randomized Study. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 3562-3567.	3.6	232
18	The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism. European Thyroid Journal, 2015, 4, 149-163.	2.4	225

#	Article	IF	CITATIONS
19	Diagnosis and management of Graves disease: a global overview. Nature Reviews Endocrinology, 2013, 9, 724-734.	9.6	215
20	Extrathyroidal manifestations of Graves' disease: a 2014 update. Journal of Endocrinological Investigation, 2014, 37, 691-700.	3.3	198
21	More on smoking habits and Graves' ophthalmopathy. Journal of Endocrinological Investigation, 1989, 12, 733-737.	3.3	187
22	Management of Graves' Ophthalmopathy: Reality and Perspectives. , 2000, 21, 168-199.		183
23	Treatment of amiodarone-induced thyrotoxicosis, a difficult challenge: results of a prospective study Journal of Clinical Endocrinology and Metabolism, 1996, 81, 2930-2933.	3.6	180
24	Effects of amiodarone administration during pregnancy on neonatal thyroid function and subsequent neurodevelopment. Journal of Endocrinological Investigation, 2001, 24, 116-130.	3.3	179
25	Color Flow Doppler Sonography Rapidly Differentiates Type I and Type II Amiodarone-Induced Thyrotoxicosis. Thyroid, 1997, 7, 541-545.	4.5	173
26	Thyroid function differently affects serum cystatin Cand creatinine concentrations. Journal of Endocrinological Investigation, 2005, 28, 346-349.	3.3	172
27	Approach to the Patient with Amiodarone-Induced Thyrotoxicosis. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 2529-2535.	3.6	166
28	2018 European Thyroid Association (ETA) Guidelines for the Management of Amiodarone-Associated Thyroid Dysfunction. European Thyroid Journal, 2018, 7, 55-66.	2.4	165
29	Treatment of amiodarone-induced thyrotoxicosis, a difficult challenge: results of a prospective study. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 2930-2933.	3.6	160
30	Acute and Severe Liver Damage Associated with Intravenous Glucocorticoid Pulse Therapy in Patients with Graves' Ophthalmopathy. Thyroid, 2004, 14, 403-406.	4.5	151
31	Orbital radiotherapy combined with high dose systemic glucocorticoids for Graves' ophthalmopathy is more effective than radiotherapy alone: results of a prospective randomized study. Journal of Endocrinological Investigation, 1991, 14, 853-860.	3.3	149
32	A 2013 European survey of clinical practice patterns in the management of Graves' disease. Clinical Endocrinology, 2016, 84, 115-120.	2.4	148
33	The Various Effects of Amiodarone on Thyroid Function. Thyroid, 2001, 11, 511-519.	4.5	135
34	Epidemiology, Natural History, Risk Factors, and Prevention of Graves' Orbitopathy. Frontiers in Endocrinology, 2020, 11, 615993.	3.5	132
35	Serum interleukin-6 in amiodarone-induced thyrotoxicosis Journal of Clinical Endocrinology and Metabolism, 1994, 78, 423-427.	3.6	129
36	Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial. Lancet Diabetes and Endocrinology,the, 2018, 6, 287-298.	11.4	128

#	Article	IF	CITATIONS
37	Studies on the occurrence of ophthalmopathy in Graves' disease. European Journal of Endocrinology, 1989, 120, 473-478.	3.7	127
38	ORBITAL COBALT IRRADIATION COMBINED WITH RETROBULBAR OR SYSTEMIC CORTICOSTEROIDS FOR GRAVES' OPHTHALMOPATHY: A COMPARATIVE STUDY. Clinical Endocrinology, 1987, 27, 33-42.	2.4	122
39	Effects of Total Thyroid Ablation Versus Near-Total Thyroidectomy Alone on Mild to Moderate Graves' Orbitopathy Treated with Intravenous Glucocorticoids. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1653-1658.	3.6	121
40	Recent Achievements in Studies on Thyroid Hormone-Binding Proteins*. Endocrine Reviews, 1990, 11, 47-64.	20.1	117
41	Lower Dose Prednisone Prevents Radioiodine-Associated Exacerbation of Initially Mild or Absent Graves' Orbitopathy: A Retrospective Cohort Study. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 1333-1337.	3.6	117
42	Thyroid vascularity and blood flow are not dependent on serum thyroid hormone levels: studies in vivo by color flow doppler sonography. European Journal of Endocrinology, 1999, 140, 452-456.	3.7	113
43	Graves' orbitopathy as a rare disease in Europe: a European Group on Graves' Orbitopathy (EUGOGO) position statement. Orphanet Journal of Rare Diseases, 2017, 12, 72.	2.7	113
44	Fatal and non-fatal adverse events of glucocorticoid therapy for Graves' orbitopathy: a questionnaire survey among members of the European Thyroid Association. European Journal of Endocrinology, 2012, 166, 247-253.	3.7	112
45	AMIODARONE IODINEâ€INDUCED HYPOTHYROIDISM: RISK FACTORS AND FOLLOWâ€UP IN 28 CASES. Clinical Endocrinology, 1987, 26, 227-237.	2.4	108
46	Cigarette smoking and the thyroid. European Journal of Endocrinology, 1995, 133, 507-512.	3.7	108
47	Long-Term Safety of Orbital Radiotherapy for Graves' Ophthalmopathy. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 3561-3566.	3.6	105
48	Serum interleukin-6 in amiodarone-induced thyrotoxicosis. Journal of Clinical Endocrinology and Metabolism, 1994, 78, 423-427.	3.6	103
49	The Dilemma of How to Manage Graves' Hyperthyroidism in Patients with Associated Orbitopathy. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 592-599.	3.6	94
50	PREGO (presentation of Graves' orbitopathy) study: changes in referral patterns to European Group On Graves' Orbitopathy (EUGOGO) centres over the period from 2000 to 2012. British Journal of Ophthalmology, 2015, 99, 1531-1535.	3.9	92
51	Adverse Effects of Thyroid Hormone Preparations and Antithyroid Drugs. Drug Safety, 1996, 15, 53-63.	3.2	88
52	High prevalence of subacute thyroiditis during summer season in Italy. Journal of Endocrinological Investigation, 1987, 10, 321-323.	3.3	87
53	Efficacy and Safety of Orbital Radiotherapy for Graves' Orbitopathy. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 3857-3865.	3.6	87
54	Vitreous Substitutes: The Present and the Future. BioMed Research International, 2014, 2014, 1-12.	1.9	86

#	Article	IF	CITATIONS
55	The course of Graves' ophthalmopathy is not influenced by near total thyroidectomy: a case-control study. Clinical Endocrinology, 1999, 51, 503-508.	2.4	85
56	Orbital Radiotherapy for Graves' Ophthalmopathy. Thyroid, 2002, 12, 245-250.	4.5	85
57	Relationship of the increased serum interleukin-6 concentration to changes of thyroid function in nonthyroidal illness. Journal of Endocrinological Investigation, 1994, 17, 269-274.	3.3	84
58	Role of cytokines in the pathogenesis of the euthyroid sick syndrome. European Journal of Endocrinology, 1998, 138, 603-614.	3.7	84
59	Variations in Thyroid Hormone Transport Proteins and Their Clinical Implications. Thyroid, 1992, 2, 237-245.	4.5	81
60	Relationship Between Graves' Ophthalmopathy and Type of Treatment of Graves' Hyperthyroidism. Thyroid, 1992, 2, 171-178.	4.5	81
61	Treating severe Graves' ophthalmopathy. Bailliere's Clinical Endocrinology and Metabolism, 1997, 11, 521-536.	1.0	80
62	Diagnosis and management of amiodarone-induced thyrotoxicosis in Europe: results of an international survey among members of the European Thyroid Association. Clinical Endocrinology, 2004, 61, 494-502.	2.4	78
63	Treatment of Type II Amiodarone-Induced Thyrotoxicosis by Either Iopanoic Acid or Glucocorticoids: A Prospective, Randomized Study. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 1999-2002.	3.6	77
64	Graves' ophthalmopathy: State of the art and perspectives. Journal of Endocrinological Investigation, 2004, 27, 295-301.	3.3	77
65	Diagnosis and management of amiodaroneâ€induced thyrotoxicosis: similarities and differences between North American and European thyroidologists*. Clinical Endocrinology, 2008, 69, 812-818.	2.4	75
66	Impact of Lithium on Efficacy of Radioactive Iodine Therapy for Graves' Disease: A Cohort Study on Cure Rate, Time to Cure, and Frequency of Increased Serum Thyroxine After Antithyroid Drug Withdrawal. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 201-208.	3.6	75
67	COMPARISON BETWEEN THYROID STIMULATING AND TSHâ€BINDING INHIBITING IMMUNOGLOBULINS OF GRAVES' DISEASE. Clinical Endocrinology, 1981, 15, 175-182.	2.4	74
68	Prevalence and Functional Significance of Antipituitary Antibodies in Patients with Autoimmune and Non-Autoimmune Thyroid Diseases. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 2176-2181.	3.6	74
69	The American Thyroid Association/American Association of Clinical Endocrinologists Guidelines for Hyperthyroidism and Other Causes of Thyrotoxicosis: A European Perspective. Thyroid, 2011, 21, 585-591.	4.5	74
70	Nocturnal Serum Thyrotropin (TSH) Surge and the TSH Response to TSH-Releasing Hormone: Dissociated Behavior in Untreated Depressives*. Journal of Clinical Endocrinology and Metabolism, 1990, 71, 650-655.	3.6	72
71	Oxidative stress and Graves' ophthalmopathy: <i>In vitro</i> studies and therapeutic implications. BioFactors, 2003, 19, 155-163.	5.4	71
72	The interplay between thyroid and liver: implications for clinical practice. Journal of Endocrinological Investigation, 2020, 43, 885-899.	3.3	71

#	Article	IF	CITATIONS
73	Glucocorticoid Response in Amiodarone-Induced Thyrotoxicosis Resulting from Destructive Thyroiditis Is Predicted by Thyroid Volume and Serum Free Thyroid Hormone Concentrations. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 556-562.	3.6	70
74	Prevalence and natural history of Graves' orbitopathy in the XXI century. Journal of Endocrinological Investigation, 2013, 36, 444-9.	3.3	70
75	Treatment with Lithium Prevents Serum Thyroid Hormone Increase after Thionamide Withdrawal and Radioiodine Therapy in Patients with Graves' Disease. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 4490-4495.	3.6	69
76	Graves' ophthalmopathy: a preventable disease?. European Journal of Endocrinology, 2002, 146, 457-461.	3.7	69
77	Factors Affecting Suppression of Endogenous Thyrotropin Secretion by Thyroxine Treatment: Retrospective Analysis in Athyreotic and Goitrous Patients*. Journal of Clinical Endocrinology and Metabolism, 1987, 64, 849-855.	3.6	68
78	Prevention of Graves' ophthalmopathy. Best Practice and Research in Clinical Endocrinology and Metabolism, 2012, 26, 371-379.	4.7	67
79	Amiodarone and the thyroid: a 2012 update. Journal of Endocrinological Investigation, 2012, 35, 340-8.	3.3	66
80	Interleukin-6: a marker of thyroid-destructive processes?. Journal of Clinical Endocrinology and Metabolism, 1994, 79, 1424-1427.	3.6	64
81	Management of hyperthyroidism due to Graves' disease: frequently asked questions and answers (if) Tj ETÇ	0q1 <u>1 0</u> .784	4314 rgBT /⊙∖ 64
82	Thyroid color flow doppler sonography and radioiodine uptake in 55 consecutive patients with amiodarone-induced thyrotoxicosis. Journal of Endocrinological Investigation, 2003, 26, 635-640.	3.3	62
83	HUMAN SERUM THYROTROPHIN MEASUREMENT BY ULTRASENSITIVE IMMUNORADIOMETRIC ASSAY AS A FIRSTâ€LINE TEST IN THE EVALUATION OF THYROID FUNCTION. Clinical Endocrinology, 1986, 24, 141-148.	2.4	60
84	Neuropsychological assessment in schoolchildren from an area of moderate iodine deficiency. Journal of Endocrinological Investigation, 1990, 13, 427-431.	3.3	59
85	Increased serum interleukin-6 concentration in patients with subacute thyroiditis: relationship with concomitant changes in serum T4-binding globulin concentration. Journal of Endocrinological Investigation, 1993, 16, 213-218.	3.3	59
86	Graves' Disease Occurring after Subacute Thyroiditis: Report of a Case and Review of the Literature. Thyroid, 1996, 6, 345-348.	4.5	59
87	Predictive score for the development or progression of Graves' orbitopathy in patients with newly diagnosed Graves' hyperthyroidism. European Journal of Endocrinology, 2018, 178, 635-643.	3.7	59
88	The Nocturnal Serum Thyrotropin Surge is Abolished in Patients with Adrenocorticotropin (ACTH)-Dependent or ACTH-Independent Cushing's Syndrome. Journal of Clinical Endocrinology and Metabolism, 1991, 72, 1195-1199.	3.6	58
89	Total Thyroidectomy in Patients with Amiodarone-Induced Thyrotoxicosis and Severe Left Ventricular Systolic Dysfunction. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 3515-3521.	3.6	58
90	Radioactive iodine thyroid uptake in patients with amiodarone-iodine-induced thyroid dysfunction. European Journal of Endocrinology, 1988, 119, 167-173.	3.7	57

#	Article	IF	CITATIONS
91	Graves' Orbitopathy: Imperfect Treatments for a Rare Disease. European Thyroid Journal, 2013, 2, 259-269.	2.4	57
92	Does early response to intravenous glucocorticoids predict the final outcome in patients with moderate-to-severe and active Graves' orbitopathy?. Journal of Endocrinological Investigation, 2017, 40, 547-553.	3.3	57
93	RECIPROCAL CHANGES OF SERUM THYROGLOBULIN AND TSH IN RESIDENTS OF A MODERATE ENDEMIC GOITRE AREA. Clinical Endocrinology, 1985, 23, 115-122.	2.4	56
94	Antithyroid drug treatment for Graves' disease: baseline predictive models of relapse after treatment for a patient-tailored management. Journal of Endocrinological Investigation, 2018, 41, 1425-1432.	3.3	54
95	Lack of Nocturnal Serum Thyrotropin Surge after Surgery*. Journal of Clinical Endocrinology and Metabolism, 1990, 70, 293-296.	3.6	52
96	Evaluation of thyroid function in patients with rapid-cycling and non-rapid-cycling bipolar disorder. Psychiatry Research, 1990, 34, 13-17.	3.3	52
97	Glucocorticoids Are Preferable to Thionamides as First-Line Treatment for Amiodarone-Induced Thyrotoxicosis due to Destructive Thyroiditis: A Matched Retrospective Cohort Study. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 3757-3762.	3.6	51
98	The phenotype of newly diagnosed Graves' disease in Italy in recent years is milder than in the past: results of a large observational longitudinal study. Journal of Endocrinological Investigation, 2016, 39, 1445-1451.	3.3	51
99	Thyroid Autoimmunity and Environment. Hormone and Metabolic Research, 2009, 41, 436-442.	1.5	50
100	Effects of selenium on short-term control of hyperthyroidism due to Graves' disease treated with methimazole: results of a randomized clinical trial. Journal of Endocrinological Investigation, 2017, 40, 281-287.	3.3	50
101	Color flow doppler sonography in thyrotoxicosis factitia. Journal of Endocrinological Investigation, 1996, 19, 603-606.	3.3	49
102	Amiodarone-induced thyrotoxicosis: a difficult diagnostic and therapeutic challenge*. Clinical Endocrinology, 2002, 56, 23-24.	2.4	49
103	Continuation of Amiodarone Delays Restoration of Euthyroidism in Patients with Type 2 Amiodarone-Induced Thyrotoxicosis Treated with Prednisone: A Pilot Study. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 3374-3380.	3.6	49
104	Evaluation of the Nocturnal Serum Thyrotropin (TSH) Surge, as Assessed by TSH Ultrasensitive Assay, in Patients Receiving Long Term <scp>l</scp> -Thyroxine Suppression Therapy and in Patients with Various Thyroid Disorders*. Journal of Clinical Endocrinology and Metabolism, 1987, 65, 1265-1271.	3.6	48
105	Identification of Acromegalic Patients at Risk of Developing Colonic Adenomas. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 1351-1356.	3.6	48
106	Proportion of type 1 and type 2 amiodarone-induced thyrotoxicosis has changed over a 27-year period in Italy. Clinical Endocrinology, 2007, 67, 070611013542001-???.	2.4	47
107	Controversies in radioiodine therapy: relation to ophthalmopathy, the possible radioprotective effect of antithyroid drugs, and use in large goitres. European Journal of Endocrinology, 2002, 147, 1-11.	3.7	46
108	Iopanoic acid rapidly controls Type I amiodarone-induced thyrotoxicosis prior to thyroidectomy. Journal of Endocrinological Investigation, 2002, 25, 176-180.	3.3	46

#	Article	IF	CITATIONS
109	Autoimmune hepatitis during intravenous glucocorticoid pulse therapy for Graves' ophthalmopathy treated successfully with glucocorticoids themselves. Journal of Endocrinological Investigation, 2005, 28, 280-284.	3.3	46
110	Effects of a mixture of polychlorinated biphenyls (Aroclor 1254) on the transcriptional activity of thyroid hormone receptor. Journal of Endocrinological Investigation, 2003, 26, 972-978.	3.3	45
111	Long-term outcome of thyroid function after amiodarone-induced thyrotoxicosis, as compared to subacute thyroiditis. Journal of Endocrinological Investigation, 2006, 29, 694-699.	3.3	45
112	An update on medical management of Graves' ophthalmopathy. Journal of Endocrinological Investigation, 2005, 28, 469-478.	3.3	44
113	Effects of treatment modalities for Graves' hyperthyroidism on Graves' orbitopathy: a 2015 Italian Society of Endocrinology Consensus Statement. Journal of Endocrinological Investigation, 2015, 38, 481-487.	3.3	44
114	The onset time of amiodarone-induced thyrotoxicosis (AIT) depends on AIT type. European Journal of Endocrinology, 2014, 171, 363-368.	3.7	43
115	Relationship between management of hyperthyroidism and course of the ophthalmopathy. Journal of Endocrinological Investigation, 2004, 27, 288-294.	3.3	41
116	Orbital Radiotherapy for Graves' Ophthalmopathy. Thyroid, 1998, 8, 439-441.	4.5	39
117	Orbital radiotherapy for Graves' ophthalmopathy: Useful or useless? Safe or dangerous?. Journal of Endocrinological Investigation, 2003, 26, 5-16.	3.3	39
118	Glucocorticoids for Graves' Ophthalmopathy: How and When1. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 5497-5499.	3.6	39
119	Interleukin-6 and the thyroid. European Journal of Endocrinology, 1995, 132, 386-393.	3.7	37
120	PPARgamma inhibits GH synthesis and secretion and increases apoptosis of pituitary GH-secreting adenomas. European Journal of Endocrinology, 2004, 150, 863-875.	3.7	37
121	Current concepts regarding Graves' orbitopathy. Journal of Internal Medicine, 2022, 292, 692-716.	6.0	37
122	Radio-receptor assay of TSH: its use to detect thyroid-stimulating immunoglobulins. Journal of Endocrinological Investigation, 1978, 1, 17-24.	3.3	36
123	Recommendations for treatment of hypothyroidism with levothyroxine and levotriiodothyronine: a 2016 position statement of the Italian Society of Endocrinology and the Italian Thyroid Association. Journal of Endocrinological Investigation, 2016, 39, 1465-1474.	3.3	36
124	Comparison Between Total Thyroidectomy and Medical Therapy for Amiodarone-Induced Thyrotoxicosis. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 242-251.	3.6	36
125	Serum thyrotropin by ultrasensitive immunoradiometric assay and serum free thyroid hormones in pregnancy. Journal of Endocrinological Investigation, 1986, 9, 185-189.	3.3	35
126	Outcome Prediction of Treatment of Graves' Hyperthyroidism with Antithyroid Drugs. Hormone and Metabolic Research, 2015, 47, 767-772.	1.5	34

#	Article	IF	CITATIONS
127	Management of amiodarone-induced thyrotoxicosis in Latin America: an electronic survey. Clinical Endocrinology, 2006, 65, 433-438.	2.4	33
128	Amiodaron i tarczyca. Endokrynologia Polska, 2015, 66, 176-196.	1.0	32
129	Polymorphism of Human Thyroxine-Binding Globulin. Journal of Clinical Endocrinology and Metabolism, 1983, 57, 1186-1192.	3.6	31
130	Octreotide treatment does not affect the size of most nonfunctioning pituitary adenomas. Journal of Endocrinological Investigation, 1993, 16, 541-543.	3.3	31
131	Mutations in the SLC26A4 (pendrin) gene in patients with sensorineural deafness and enlarged vestibular aqueduct. Journal of Endocrinological Investigation, 2004, 27, 430-435.	3.3	31
132	Role of autoimmune and familial factors in goiter prevalence. Studies performed in a moderately endemic area. Journal of Endocrinological Investigation, 1986, 9, 161-164.	3.3	30
133	Pituitary apoplexy during pregnancy: a rare, but dangerous headache. Journal of Endocrinological Investigation, 2014, 37, 789-797.	3.3	29
134	Therapeutic controversies. Radioiodine may be bad for Graves' ophthalmopathy, but Journal of Clinical Endocrinology and Metabolism, 1995, 80, 342-345.	3.6	27
135	Desethylamiodarone antagonizes the effect of thyroid hormone at the molecular level. European Journal of Endocrinology, 2001, 145, 59-64.	3.7	27
136	Thyroid hormone transport proteins. Clinics in Laboratory Medicine, 1993, 13, 583-98.	1.4	27
137	Therapy of Graves' disease with sodium ipodate is associated with a high recurrence rate of hyperthyroidism. Journal of Endocrinological Investigation, 1991, 14, 847-851.	3.3	26
138	Interleukin 6 effects on the pituitary–thyroid axis in the rat. European Journal of Endocrinology, 1994, 131, 302-306.	3.7	26
139	Study of serum 3,5,3′-triiodothyronine sulfate concentration in patients with systemic non-thyroidal illness. European Journal of Endocrinology, 1996, 134, 45-49.	3.7	26
140	The age of patients with thyrotoxicosis factitia in Italy from 1973 to 1996. Journal of Endocrinological Investigation, 1999, 22, 128-133.	3.3	26
141	A novel mutation in the pendrin gene associated with Pendred's syndrome. Clinical Endocrinology, 2000, 52, 279-285.	2.4	26
142	Immunomodulatory effect of vitamin D and its potential role in the prevention and treatment of thyroid autoimmunity: a narrative review. Journal of Endocrinological Investigation, 2020, 43, 413-429.	3.3	26
143	l-thyroxine directly affects expression of thyroid hormone-sensitive genes: regulatory effect of RXRβ. Molecular and Cellular Endocrinology, 1997, 134, 23-31.	3.2	25
144	Amiodarone-induced thyrotoxicosis: something new to refine the initial diagnosis?. European Journal of Endocrinology, 2008, 159, 359-361.	3.7	25

#	Article	IF	CITATIONS
145	Thyroid hormone regulation of cell migration and oxidative metabolism in polymorphonuclear leukocytes: Clinical evidence in thyroidectomized subjects on thyroxine replacement therapy. Life Sciences, 2006, 78, 1071-1077.	4.3	24
146	Surgery of lymph nodes in papillary thyroid cancer. Expert Review of Anticancer Therapy, 2006, 6, 1217-1229.	2.4	24
147	Novel Immunomodulating Agents for Graves Orbitopathy. Ophthalmic Plastic and Reconstructive Surgery, 2008, 24, 251-256.	0.8	24
148	The presence of anti-thyroglobulin (TgAb) and/or anti-thyroperoxidase antibodies (TPOAb) does not exclude the diagnosis of type 2 amiodarone-induced thyrotoxicosis. Journal of Endocrinological Investigation, 2016, 39, 585-591.	3.3	24
149	Macular Hole Surgery: The Healing Process of Outer Retinal Layers to Visual Acuity Recovery. European Journal of Ophthalmology, 2017, 27, 235-239.	1.3	24
150	Management of Subclinical Hypothyroidism in Pregnancy: A Comment from the Italian Society of Endocrinology and the Italian Thyroid Association to the 2017 American Thyroid Association Guidelines—"The Italian Way― Thyroid, 2018, 28, 551-555.	4.5	24
151	Change in newly diagnosed Graves' disease phenotype between the twentieth and the twenty-first centuries: meta-analysis and meta-regression. Journal of Endocrinological Investigation, 2021, 44, 1707-1718.	3.3	24
152	Effects of interleukin-6 on the expression of thyroid hormone-binding protein genes in cultured human hepatoblastoma-derived (Hep G2) cells. Molecular Endocrinology, 1992, 6, 935-942.	3.7	23
153	Management of thyroid eye disease. European Journal of Nuclear Medicine and Molecular Imaging, 2002, 29, S458-S465.	6.4	23
154	Proposal for Standardization of Primary and Secondary Outcomes in Patients with Active, Moderate-to-Severe Graves' Orbitopathy. European Thyroid Journal, 2020, 9, 3-16.	2.4	23
155	Immunological Drivers in Graves' Disease: NK Cells as a Master Switcher. Frontiers in Endocrinology, 2020, 11, 406.	3.5	23
156	Cytokine antagonists: new ideas for the management of Graves' ophthalmopathy. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 446-448.	3.6	23
157	Soluble interleukin-1 receptor antagonist concentration in patients with Graves' ophthalmopathy is neither related to cigarette smoking nor predictive of subsequent response to glucocorticoids. Clinical Endocrinology, 2000, 52, 647-651.	2.4	22
158	CH Secretion Is Impaired in Patients with Primary Hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 1961-1964.	3.6	22
159	Apoptosis is reduced in the colonic mucosa of patients with acromegaly. Clinical Endocrinology, 2005, 63, 683-688.	2.4	22
160	What to do for moderateâ€ŧoâ€severe and active Graves' orbitopathy if glucocorticoids fail?. Clinical Endocrinology, 2010, 73, 149-152.	2.4	22
161	Teprotumumab for Graves' orbitopathy and ototoxicity: moving problems from eyes to ears?. Journal of Endocrinological Investigation, 2022, 45, 1455-1457.	3.3	22
162	Dissociation of Responsiveness to Thyrotropin-Releasing Hormone and Thyroid Suppressibility Following Antithyroid Drug Therapy of Hyperthyroidism. Journal of Clinical Endocrinology and Metabolism, 1976, 43, 543-549.	3.6	21

#	Article	IF	CITATIONS
163	Somatostatin Analogs for Graves' Ophthalmopathy: Do They Bounce Off like a Rubber Bullet?. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 5908-5909.	3.6	21
164	Relation between Graves' orbitopathy and radioiodine therapy for hyperthyroidism: facts and unsolved questions*. Clinical Endocrinology, 2008, 69, 845-847.	2.4	21
165	Studies on thyroid cell surface antigens using cultured human thyroid cells. Clinical and Experimental Immunology, 1982, 47, 336-44.	2.6	20
166	Effect of tunicamycin and monensin on secretion of thyroxine-binding globulin by cultured human hepatoma (Hep G2) cells. Journal of Biological Chemistry, 1984, 259, 13610-4.	3.4	20
167	Graves' hyperthyroidism and ophthalmopathy associated with pemphigus vulgaris: Onset of thyroid autoimmune disease during chronic low-dose glucocorticoid therapy. Journal of Endocrinological Investigation, 1997, 20, 155-157.	3.3	19
168	Smoking and Graves' disease. Journal of Endocrinological Investigation, 2002, 25, 402-402.	3.3	19
169	Changes in the Expression of the Peroxisome Proliferator-Activated Receptor Î ³ Gene in the Colonic Polyps and Colonic Mucosa of Acromegalic Patients. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 3938-3942.	3.6	19
170	Masked hypertension in newly diagnosed hypothyroidism: a pilot study. Journal of Endocrinological Investigation, 2016, 39, 1131-1138.	3.3	19
171	Management of Graves' hyperthyroidism and orbitopathy in time of COVID-19 pandemic. Journal of Endocrinological Investigation, 2020, 43, 1149-1151.	3.3	19
172	Will biological agents supplant systemic glucocorticoids as the first-line treatment for thyroid-associated ophthalmopathy?. European Journal of Endocrinology, 2019, 181, D27-D43.	3.7	19
173	Management of Graves' hyperthyroidism: present and future. Expert Review of Endocrinology and Metabolism, 2022, 17, 153-166.	2.4	19
174	Glucocorticoids and outcome of radioactive iodine therapy for Graves' hyperthyroidism. European Journal of Endocrinology, 2005, 153, 13-14.	3.7	18
175	Plasma total and acylated Ghrelin concentrations in patients with clinical and subclinical thyroid dysfunction. Journal of Endocrinological Investigation, 2009, 32, 74-78.	3.3	18
176	Features and outcome of differentiated thyroid carcinoma associated with Graves' disease: results of a large, retrospective, multicenter study. Journal of Endocrinological Investigation, 2020, 43, 109-116.	3.3	18
177	Diagnosis of amiodarone-iodine-induced thyrotoxicosis(AIIT) associated with severe nonthyroidal illness. Journal of Endocrinological Investigation, 1987, 10, 589-591.	3.3	17
178	The Lack of Nocturnal Serum Thyrotropin Surge in Patients with Nontoxic Nodular Goiter May Predict the Subsequent Occurrence of Hyperthyroidism*. Journal of Clinical Endocrinology and Metabolism, 1991, 73, 604-608.	3.6	17
179	Thyroid Color Flow Doppler Sonography: An Adjunctive Tool for Differentiating Patients with Inappropriate Thyrotropin (TSH) Secretion Due to TSH-Secreting Pituitary Adenoma or Resistance to Thyroid Hormone. Thyroid, 2006, 16, 989-995.	4.5	17
180	Teprotumumab: a new avenue for the management of moderate-to-severe and active Graves' orbitopathy?. Journal of Endocrinological Investigation, 2017, 40, 885-887.	3.3	17

#	Article	IF	CITATIONS
181	Cardiometabolic healthy and unhealthy obesity: does vitamin D play a role?. Endocrine Connections, 2017, 6, 943-951.	1.9	17
182	Relationship between nocturnal serum thyrotropin peak and metabolic control in diabetic patients. Journal of Clinical Endocrinology and Metabolism, 1993, 76, 983-987.	3.6	17
183	Add-On Effect of Selenium and Vitamin D Combined Supplementation in Early Control of Graves' Disease Hyperthyroidism During Methimazole Treatment. Frontiers in Endocrinology, 0, 13, .	3.5	17
184	Thyroid vascularity is increased in patients with active acromegaly. Clinical Endocrinology, 2002, 57, 65-70.	2.4	16
185	Effects of Amiodarone, Thyroid Hormones and CYP2C9 and VKORC1 Polymorphisms on Warfarin Metabolism: A Review of the Literature. Endocrine Practice, 2013, 19, 1043-1049.	2.1	16
186	A teleconsultation network improves the efficacy of anti-VEGF therapy in retinal diseases. Journal of Telemedicine and Telecare, 2013, 19, 437-442.	2.7	16
187	Characterization of nascent and secreted thyroxine-binding globulin in cultured human hepatoma (Hep G2) cells. Journal of Biological Chemistry, 1984, 259, 13605-9.	3.4	16
188	Levothyroxine suppressive therapy: Harmful and useless or harmless and useful?. Journal of Endocrinological Investigation, 1994, 17, 675-677.	3.3	15
189	Interleukin-6 Levels are not Increased in Women with Postpartum Thyroid Dysfunction. Thyroid, 1998, 8, 371-375.	4.5	15
190	Adjuvant Effect of Lithium on Radioiodine Treatment of Hyperthyroidism. Thyroid, 2002, 12, 1153-1154.	4.5	15
191	Medullary thyroid carcinoma: surgical treatment advances. Expert Review of Anticancer Therapy, 2007, 7, 877-885.	2.4	15
192	Graves'-like orbitopathy: do not forget IgG4-related disease. Journal of Endocrinological Investigation, 2014, 37, 1233-1235.	3.3	15
193	Commentary. Ophthalmic Plastic and Reconstructive Surgery, 2014, 30, 420-423.	0.8	15
194	Treatment of Graves' hyperthyroidism with thionamides: a position paper on indications and safety in pregnancy. Journal of Endocrinological Investigation, 2020, 43, 257-265.	3.3	15
195	Asymmetry indicates more severe and active disease in Graves' orbitopathy: results from a prospective cross-sectional multicentre study. Journal of Endocrinological Investigation, 2020, 43, 1717-1722.	3.3	15
196	Novel Approaches to the Management of Graves` Ophthalmopathy. Hormones, 2002, 1, 76-90.	1.9	15
197	Cigarette smoking: number one enemy for Graves ophthalmopathy. Polish Archives of Internal Medicine, 2016, 126, 725-726.	0.4	15
198	The dilemma of non-thyroidal illness syndrome: to treat or not to treat?. Journal of Endocrinological Investigation, 2003, 26, 1162-1162.	3.3	14

#	Article	IF	CITATIONS
199	Potassium perchlorate only temporarily restores euthyroidism in patients with amiodarone-induced hypothyroidism who continue amiodarone therapy. Journal of Endocrinological Investigation, 2008, 31, 515-519.	3.3	14
200	Physical performance in newly diagnosed hypothyroidism: a pilot study. Journal of Endocrinological Investigation, 2017, 40, 1099-1106.	3.3	14
201	Role of oxidative stress and selenium in Graves' hyperthyroidism and orbitopathy. Journal of Endocrinological Investigation, 2013, 36, 15-20.	3.3	14
202	Glucocorticoid administration for Graves' hyperthyroidism treated by radioiodine. A questionnaire survey among members of the European Thyroid Association. Journal of Endocrinological Investigation, 2010, 33, 409-413.	3.3	13
203	Duration of Exposure to Thyrotoxicosis Increases Mortality of Compromised AIT Patients: the Role of Early Thyroidectomy. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3427-e3436.	3.6	13
204	Effect of high-dose intravenous glucocorticoid therapy on serum thyroid hormone concentrations in type 2 amiodarone-induced thyrotoxicosis: an exploratory study. Journal of Endocrinological Investigation, 2020, 43, 1637-1643.	3.3	13
205	Subclinical hypothyroidism and deep venous thrombosis. A pilot cross-sectional study. Thrombosis and Haemostasis, 2007, 97, 803-6.	3.4	13
206	The effect of altered thyroid function on serum fructosamine concentrations. Clinical Biochemistry, 1988, 21, 179-181.	1.9	12
207	Pendrin does not increase sulfate uptake in mammalian COS-7 cells. Journal of Endocrinological Investigation, 2000, 23, 170-172.	3.3	12
208	An update on the pharmacological management of hyperthyroidism due to Graves' disease. Expert Opinion on Pharmacotherapy, 2005, 6, 851-861.	1.8	12
209	Graves' hyperthyroidism of recent onset and Graves' orbitopathy: To ablate or not to ablate the thyroid?. Journal of Endocrinological Investigation, 2008, 31, 578-581.	3.3	12
210	Nodule size and fine-needle aspiration biopsy: diagnostic challenges for thyroid malignancy. American Journal of Surgery, 2011, 201, 525-530.	1.8	12
211	Oral steroid prophylaxis for Graves' orbitopathy after radioactive iodine treatment for Graves' disease is not only effective, but also safe. Journal of Endocrinological Investigation, 2020, 43, 381-383.	3.3	12
212	Graves' disease and Turner's syndrome. Journal of Endocrinological Investigation, 1980, 3, 429-431.	3.3	11
213	Is thyroxine during lithium therapy necessary?. Journal of Endocrinological Investigation, 1999, 22, 220-222.	3.3	11
214	Analysis of voice in patients with untreated active acromegaly. Journal of Endocrinological Investigation, 2010, 33, 178-185.	3.3	10
215	Improvement of Growth Hormone Deficiency in Patients with Primary Hyperparathyroidism after Parathyroidectomy: Results of a Prospective Study. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 1213-1216.	3.6	10
216	Measurement of thyroid cell surface antibodies by radioassay using human cultured thyroid cells. Journal of Endocrinological Investigation, 1981, 4, 439-444.	3.3	9

#	Article	IF	CITATIONS
217	Serum free thyroid hormones in subclinical hypothyroidism. Journal of Endocrinological Investigation, 1986, 9, 315-319.	3.3	9
218	Absence of serum thyroid hormone autoantibodies in patients chronically treated with amiodarone. Journal of Endocrinological Investigation, 1988, 11, 323-325.	3.3	9
219	Non-autoimmune hyperthyroidism associated with isolated bilateral ocular lymphoma mimicking Graves' disease with ophthalmopathy: A cause of misdiagnosis. Journal of Endocrinological Investigation, 1995, 18, 817-819.	3.3	9
220	Changes in the expression of suppressor of cytokine signalling (SOCS) 2 in the colonic mucosa of acromegalic patients are associated with hyperplastic polyps. Clinical Endocrinology, 2009, 70, 898-906.	2.4	9
221	Selenium in the Treatment of Thyroid Diseases. European Thyroid Journal, 2017, 6, 113-114.	2.4	9
222	The differentiation-inducing agent sodium butyrate produces divergent effects on albumin and thyroxine-binding globulin synthesis by human hepatoblastoma-derived (Hep G2) cells. Journal of Endocrinological Investigation, 1990, 13, 917-922.	3.3	8
223	Studies on thyroxine-binding globulin. Journal of Endocrinological Investigation, 1993, 16, 353-371.	3.3	8
224	Growth hormone secretion in primary and secondary hyperparathyroidism. Journal of Endocrinological Investigation, 2005, 28, 113-116.	3.3	8
225	Uptake of amiodarone by thyroidal and non-thyroidal cell lines. Journal of Endocrinological Investigation, 2006, 29, 61-66.	3.3	8
226	Amiodaroneâ€induced thyrotoxicosis, an overview of <scp>UK</scp> management. Clinical Endocrinology, 2012, 77, 936-937.	2.4	8
227	Antithyroid drugs in Graves' hyperthyroidism: differences between "block and replace―and "titration regimes in frequency of euthyroidism and Graves' orbitopathy during treatment. Journal of Endocrinological Investigation, 2021, 44, 371-378.	n― 3.3	8
228	Effects of thyroxine excess on peripheral organs. Vienna Clinical Weekly, 1994, 21, 60-5.	0.9	8
229	Changes in Radioimmunoassayable Prealbumin (TBPA) Serum Levels from Birth to Adulthood. Hormone and Metabolic Research, 1986, 18, 73-73.	1.5	7
230	Interaction of the thyrotropin receptor on rat FRTL-5 thyroid cells with thyrotropin and a thyrotropin-stimulating autoantibody from Graves' patients. Biochemical and Biophysical Research Communications, 1987, 143, 266-272.	2.1	7
231	Circadian thyrotropin variations are preserved in normal pregnant women. European Journal of Endocrinology, 1995, 133, 71-74.	3.7	7
232	Antithyroid drug treatment prior to radioiodine therapy for Graves' disease: Yes or no?. Journal of Endocrinological Investigation, 2003, 26, 174-176.	3.3	7
233	Cardiac expression of adenine nucleotide translocase-1 in transgenic mice overexpressing bovine GH. Journal of Endocrinology, 2007, 194, 521-527.	2.6	7
234	Pain Perception, Blood Pressure Levels, and Peripheral Benzodiazepine Receptors in Patients Followed for Differentiated Thyroid Carcinoma: A Longitudinal Study in Hypothyroidism and During Hormone Treatment. Clinical Journal of Pain, 2007, 23, 518-523.	1.9	7

#	Article	IF	CITATIONS
235	Can a patient-tailored treatment approach for Graves' disease reduce mortality?. Lancet Diabetes and Endocrinology,the, 2019, 7, 245-246.	11.4	7
236	Methimazole Treatment and Acute Pancreatitis: Both Caution and Reassurance Are Needed. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e4967-e4969.	3.6	7
237	Lack of nocturnal serum thyrotropin (TSH) surge in patients with chronic renal failure undergoing regular maintenance hemofiltration: a case of central hypothyroidism. Clinical Nephrology, 1990, 34, 30-4.	0.7	7
238	Free Thyroxine and Free Triiodothyronine Measurement in Dried Blood Spots on Filter Paper by Column Adsorption Chromatography Followed by Radioimmunoassay. Hormone and Metabolic Research, 1988, 20, 293-297.	1.5	6
239	Percutaneous ethanol injection: what is its role in the management of nodular lesions of endocrine glands?. European Journal of Endocrinology, 1995, 132, 300-301.	3.7	6
240	Currently available somatostatin analogs are not good for Graves' orbitopathy. Journal of Endocrinological Investigation, 2006, 29, 389-390.	3.3	6
241	Immunotherapy for Graves' orbitopathy: Easy enthusiasm, but let's keep trying. Journal of Endocrinological Investigation, 2006, 29, 1012-1016.	3.3	6
242	Changes in Autonomic Modulation to the Heart and Intracellular Catecholamines. Hormone Research in Paediatrics, 2007, 67, 171-178.	1.8	6
243	Can combination of glucocorticoids with other immunosoppressive drugs reduce the cumulative dose of glucocorticoids for moderate-to-severe and active Graves' orbitopathy?. Journal of Endocrinological Investigation, 2019, 42, 351-352.	3.3	6
244	Orbital decompression for severe Graves' ophthalmopathy. Results of a three-wall operative technique. Journal of Neurosurgical Sciences, 1989, 33, 323-7.	0.6	6
245	TSH-displacing activity versus TSH-binding inhibiting activity of immunoglobulins from patients with Graves' disease. Journal of Endocrinological Investigation, 1983, 6, 375-378.	3.3	5
246	Iodine contamination in subjects admitted to a general hospital. Journal of Endocrinological Investigation, 1992, 15, 307-308.	3.3	5
247	Circulating levels of anticonvulsant metabolites of progesterone in women with partial epilepsy in the intercritical phase. Italian Journal of Neurological Sciences, 1996, 17, 277-281.	0.1	5
248	Radioiodine and thyroid-associated ophthalmopathy. Orbit, 1996, 15, 197-203.	0.8	5
249	Primary hyperparathyroidism is associated with an impaired secretion of growth hormone but not of the other anterior pituitary hormones. Journal of Endocrinological Investigation, 2002, 25, RC7-RC9.	3.3	5
250	Reduced colonic apoptosis in mice overexpressing bovine growth hormone occurs through changes in several kinase pathways. Growth Hormone and IGF Research, 2009, 19, 432-441.	1.1	5
251	Time interval in diagnosis and treatment of papillary thyroid cancer: a descriptive, retrospective study. American Journal of Surgery, 2009, 197, 434-438.	1.8	5
252	Treating Graves' orbitopathy: where are we?. Endocrine, 2012, 41, 167-168.	2.3	5

#	Article	IF	CITATIONS
253	Steroid Prophylaxis After Radioiodine Treatment for Graves' Hyperthyroidism: Selective or Universal?. Thyroid, 2014, 24, 1441-1442.	4.5	5
254	Treatment of moderate-to-severe and active Graves' orbitopathy: a step forward from the OPTIC study. Journal of Endocrinological Investigation, 2020, 43, 1523-1525.	3.3	5
255	Thyroid autoimmunity and endemic goiter. Endocrinologia Experimentalis, 1986, 20, 49-56.	0.0	5
256	Serum TSH measurements by a sensitive enzyme immunoassay discriminate euthyroid from hyperthyroid subjects and avoid the need for TRH test during suppressive therapy with L-thyroxine. Clinical Biochemistry, 1987, 20, 197-200.	1.9	4
257	Free thyroxine values in dried blood spots on filter paper in newborns are related to both gestational age and birth body weight. Journal of Endocrinological Investigation, 1988, 11, 515-519.	3.3	4
258	Colonic polyps of acromegalic patients are not associated with mutations of the peroxisome proliferator activated receptor l ³ gene. Journal of Endocrinological Investigation, 2003, 26, 1054-1058.	3.3	4
259	Serum prostate-specific antigen concentration is increased in acromegalic women. Journal of Endocrinological Investigation, 2004, 27, 643-647.	3.3	4
260	Graves' ophthalmopathy: Search for shared autoantigen(s) continues. Journal of Endocrinological Investigation, 2005, 28, 396-397.	3.3	4
261	A thyroid nodule in a young Sicilian princess in 1900. Journal of Endocrinological Investigation, 2020, 43, 699-700.	3.3	4
262	Identification of Two Different Phenotypes of Patients with Amiodarone-Induced Thyrotoxicosis and Positive Thyrotropin Receptor Antibody Tests. Thyroid, 2021, 31, 1463-1471.	4.5	4
263	Reply to Letter to the Editor by Dr. Terry J. Smith regarding teprotumumab and ototoxicity. Journal of Endocrinological Investigation, 0, , .	3.3	4
264	Use of solubilized radioiodinated thyroid plasma membranes for purification of TSH-receptor by affinity chromatography. FEBS Letters, 1978, 88, 292-294.	2.8	3
265	Shortening hospital stay for thyroid surgery. Expert Review of Medical Devices, 2008, 5, 85-96.	2.8	3
266	Eyelid myiasis caused by <i>Cordylobia anthropophaga</i> . Ocular Immunology and Inflammation, 2015, 23, 259-260.	1.8	3
267	Serum Thyroid Hormone-Binding Proteins. , 2019, , 442-447.		3
268	The artist's wife with a simple nontoxic goiter. Journal of Endocrinological Investigation, 2020, 43, 1043-1044.	3.3	3
269	The role of somatostatin analogs in the management of Graves' ophthalmopathy. Journal of Endocrinological Investigation, 2003, 26, 109-13.	3.3	3
270	Radioiodine therapy and Graves' ophthalmopathy. Nuclear Medicine Communications, 2002, 23, 1143-1145.	1.1	2

#	Article	IF	CITATIONS
271	Abnormal expression of PPAR gamma isoforms in the subcutaneous adipose tissue of patients with Cushing's disease. Clinical Endocrinology, 2006, 66, 060904075417002-???.	2.4	2
272	The reduction of bone mineral density in postmenopausal women with primary hyperparathyroidism is higher in the presence of concomitant GH secretion impairment. European Journal of Endocrinology, 2006, 155, 41-45.	3.7	2
273	Happy Birthday, Journal of Endocrinological Investigation!. Journal of Endocrinological Investigation, 2018, 41, 1-1.	3.3	2
274	Acromegaly in digital art. Journal of Endocrinological Investigation, 2019, 42, 1387-1388.	3.3	2
275	The multinodular goiter of the virtuous Roman matron Lucretia by Artemisia Gentileschi. Journal of Endocrinological Investigation, 2020, 43, 701-702.	3.3	2
276	Graves' orbitopathy represented as feature of a state of mind. Journal of Endocrinological Investigation, 2020, 43, 1343-1344.	3.3	2
277	The Virgin Mary with a small goiter breastfeeding the Child. Journal of Endocrinological Investigation, 2021, 44, 641-642.	3.3	2
278	A young lady with goiter by Mario Sironi (1885–1961). Journal of Endocrinological Investigation, 2021, 44, 207-208.	3.3	2
279	Statins for Graves' orbitopathy: a new tool for prevention and treatment?. Lancet Diabetes and Endocrinology,the, 2021, 9, 726-727.	11.4	2
280	When primary hyperparathyroidism comes as good news. Endocrinology, Diabetes and Metabolism Case Reports, 2020, 2020, .	0.5	2
281	lodine supplementation in women of reproductive age: a survey of clinical practice among Italian gynecologists and midwives. Journal of Endocrinological Investigation, 2019, 42, 353-355.	3.3	2
282	Thyroxine uptake by human hepatoma cells from serum of patients submitted to long-term thyroxine suppressive therapy. Journal of Endocrinological Investigation, 1988, 11, 629-635.	3.3	1
283	Effects of the antileukemic drug L-asparaginase on sex hormone-binding globulin: studies in vivo and in vitro. Journal of Endocrinological Investigation, 1989, 12, 489-493.	3.3	1
284	Diagnosis of thyroid dysfunction: present and future. Nuclear Medicine and Biology, 1994, 21, 531-544.	0.6	1
285	Identification, treatment and management of cardiovascular risks in patients with acromegaly. Expert Review of Endocrinology and Metabolism, 2008, 3, 603-614.	2.4	1
286	Maria Carolina of Austria, Queen of Naples and Sicily: a possible case of Graves' orbitopathy. Journal of Endocrinological Investigation, 2017, 40, 239-240.	3.3	1
287	Graves' Orbitopathy: do not give it for granted. Endocrine, 2018, 62, 731-732.	2.3	1
288	The clinical enigma of the "Flea catcher―by Georges de La Tour: a pregnant sinner with pre-eclampsia or a hypothyroid girl?. Journal of Endocrinological Investigation, 2019, 42, 995-996.	3.3	1

#	Article	IF	CITATIONS
289	Graves' Ophthalmopathy. , 2019, , 323-337.		1
290	Response to comment by Smith on the 2021 EUGOGO guidelines. European Journal of Endocrinology, 2021, 185, L15-L16.	3.7	1
291	Thyroid function tests and diagnostic protocols for investigation of thyroid dysfunction. Annali Dell'Istituto Superiore Di Sanita, 1991, 27, 531-9.	0.4	1
292	Serum thyroid hormones and thyroid hormone binding proteins in patients with completed stroke. Annals of Clinical Research, 1986, 18, 203-7.	0.2	1
293	Novel treatment modalities for Graves' orbitopathy. Pediatric Endocrinology Reviews, 2010, 7 Suppl 2, 210-6.	1.2	1
294	La prevenzione dell'oftalmopatia basedowiana. L Endocrinologo, 2004, 5, 47-51.	0.0	0
295	Declaración de consenso del Grupo europeo sobre la orbitopatÃa de Graves (EUGOGO) sobre el tratamiento de la orbitopatÃa de Graves (OG). Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion, 2008, 55, 356.e1-356.e13.	0.8	Ο
296	Perspectives in pharmacological management of Graves' hyperthyroidism and orbitopathy. Expert Review of Clinical Immunology, 2008, 4, 321-329.	3.0	0
297	Thyroid Hormone Treatment for Differentiated Thyroid Carcinoma: What Drug, How Long, What Dose?. Current Cancer Therapy Reviews, 2009, 5, 296-302.	0.3	Ο
298	The Challenge of Orbital Decompression in a Patient with Multiple Autoimmune Diseases and Graves' Orbitopathy: A Case Report and Review of Literature. Orbit, 2010, 29, 48-50.	0.8	0
299	What is the Role of Medical Therapy in the Management of Graves' Orbitopathy?. Acta Endocrinologica, 2014, 10, 249-258.	0.3	0
300	Treatment of Hyperthyroidism in Patients with Gravesâ \in M Orbitopathy. , 2015, , 213-222.		0
301	General Management Plan for Graves' Orbitopathy. , 2017, , 105-112.		Ο
302	Treatment of Graves' Disease. Endocrinology, 2018, , 489-511.	0.1	0
303	Pituitary disorders as wonders and curiosity in XVI Century. Journal of Endocrinological Investigation, 2020, 43, 551-552.	3.3	Ο
304	Cushing syndrome at the court of the infant of Spain in the eighteenth century?. Journal of Endocrinological Investigation, 2020, 43, 871-872.	3.3	0
305	Comics' representation of Graves' orbitopathy, by Emil Ferris. Journal of Endocrinological Investigation, 2021, 44, 1799-1800.	3.3	0
306	Hyperthyroidism Due to Graves‗ Disease – Is There an Optimal Pharmacological Treatment Regimen?. European Endocrinology, 2008, 4, 63.	1.5	0

#	Article	IF	CITATIONS
307	Treatment of Graves' Disease. Endocrinology, 2016, , 1-24.	0.1	0
308	Smoking and the Thyroid. , 2018, , 719-722.		0
309	Ontogeny of Pancreatic TRH Occurs Independently of Brain Development Annals of the New York Academy of Sciences, 1989, 553, 624-625.	3.8	0